PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Basel – The Basel pharmaceutical company Novartis has announced the results of a study on its migraine drug AMG 334. Patients with episodic migraine showed an improvement.
The data comes from the Phase III ARISE study. According to a Novartis statement, a total of 577 patients with episodic migraine – defined as between 4 and 14 migraine days each month, with an average of eight migraine days per month – enrolled in the study.
One group was given AMG 334 (erenumab), the other a placebo. Those receiving AMG 334 experienced a 2.9-day reduction from baseline in monthly migraine days, as compared to a 1.8-day reduction in the placebo group.
“People who suffer from episodic migraine experience substantial pain, disability and physical impairment, which can significantly disrupt their ability to participate in everyday activities,” said Vasant Narasimhan, Chief Medical Officer for Novartis.
There are currently no treatment options specifically designed for the prevention of migraine, which makes the positive data from this study all the more encouraging.
Novartis is developing the drug together with the US biotechnology company Amgen. As part of the collaboration, Novartis has commercialisation rights in Europe and the rest of the world, excluding the US, Canada and Japan.
Migraine is the most prevalent neurological disorder in the world, affecting more than 10 per cent of the world’s population.